Onglyza®

The law firm of Slater Slater Schulman LLP is investigating complaints that type 2 diabetes treatment Onglyza® may be associated with pancreatic cancer, as well as allegations that Onglyza’s manufacturers negligently marketed and promoted the drug and failed to adequately test it or warn consumers of the risks of pancreatic cancer.

About Onglyza

Onglyza® (saxagliptin), the type 2 diabetes treatment developed and marketed by Bristol-Myers Squibb and AstraZeneca, is a pharmaceutical drug prescribed for lowering blood sugar levels in adult patients with type 2 diabetes. Type 2 diabetes affects millions of Americans and their families. Onglyza works by increasing insulin production by the pancreas and reducing the amount of sugar produced by the liver when blood sugar levels are too high. Onglyza was approved for sale in the U.S. by the Food and Drug Administration (FDA) in July 2009.

On March 14, 2013, the FDA released a Drug Safety Communication concerning Onglyza, JanuviaByetta and others in the same class of drugs, stating:

The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.

Drugs in this class work by mimicking the incretin hormones produced by the body to stimulate the release of insulin after ingesting food. Together with exercising and eating better, these drugs can help lower blood sugar levels in adults with type 2 diabetes.

While there were previous studies suggesting incretins, including Onglyza, JanuviaByetta, may been linked to pancreatitis, this recent FDA statement raises the possibility that Onglyza, JanuviaByetta may also be associated with pancreatic cancer.

Do I have a Onglyza Cancer Lawsuit?

The attorneys at Slater Slater Schulman LLP are dedicated to assisting potential plaintiffs in Onglyza pancreatic cancer lawsuits. If you or someone you love have taken Onglyza,JanuviaByetta and developed pancreatic cancer, you should contact Slater Slater Schulman LLP for a free consultation by filling out the form on this page or by calling us at (800) 251-6990.

Medical disclaimer: Please note that any change in medications should be made only after consulting with your doctor about the risks and benefits of doing so, and should not be based on any information contained in this web site or on a commercial.






Recent Articles

ATTORNEY ADVERTISING – The information on this website is for general information purposes only. Nothing on this site should be taken as legal advice for any individual case or situation. This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship. This website may constitute attorney advertising. Prior results do not guarantee a similar outcome. | Copyright 2019 Slater Slater Schulman LLP |  All Rights Reserved  |  Privacy Policy